<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113159</article-id><article-id pub-id-type="publisher-id">ACM-41015</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_22778200.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  B族链球菌病感染新生儿结局分析及检测治疗进展
  Progress in the Outcome Analysis, Detection and Treatment of Group B Streptococcal Disease Infected Newborns
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>瑶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>红梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>金梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>乔</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院妇产科学，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1112</fpage><lpage>1118</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    尽管近年来B族链球菌(group B streptococcus GBS)感染在治疗和预防方面取得了显著进步，但GBS感染仍然是重要的公共卫生问题，是导致新生儿不良结局的重要原因。目前GBS疫苗作为预防GBS感染的理想策略正处于研发阶段，部分疫苗已进入临床试验阶段。本文综述GBS感染患儿的发病率、不良结局、血清型、抗生素使用情况、耐药性和检测方法研究进展，为GBS感染患儿临床诊治，更准确的检测和疫苗的进一步研发提供参考，以期预防无法通过现有的产时抗生素(intrapartum antibiotic prophylaxis, IAP)治疗策略加以预防的婴儿GBS疾病。
    Although in recent years, the treatment and prevention of group B streptococcus (GBS) infection has made significant progress, but still GBS infection is an important public health problem, and is an important reason for adverse outcomes in newborns. The GBS vaccines, as an ideal strategy to prevent the GES infection, is in the development stage; some vaccines have entered clinical trials. This article reviews the research progress of incidence, adverse outcomes, serotypes, antibiotic use, drug resistance and detection methods in children with GBS infection, to provide reference for clinical diagnosis and treatment of children with GBS infection, more accurate detection and further development of vaccines, in order to prevent GBS diseases in infants that cannot be prevented by existing intrapartum antibiotic prophylaxis (IAP) treatment strategies. 
  
 
</p></abstract><kwd-group><kwd>B族链球菌，产时抗生素预防策略(IAP)，GBS检测方法，疫苗, Group B Streptococcus</kwd><kwd> Intrapartum Antibiotic Prophylaxis</kwd><kwd> GBS Detection Method</kwd><kwd> Vaccine</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>尽管近年来B族链球菌(group B streptococcus GBS)感染在治疗和预防方面取得了显著进步，但GBS感染仍然是重要的公共卫生问题，是导致新生儿不良结局的重要原因。目前GBS疫苗作为预防GBS感染的理想策略正处于研发阶段，部分疫苗已进入临床试验阶段。本文综述GBS感染患儿的发病率、不良结局、血清型、抗生素使用情况、耐药性和检测方法研究进展，为GBS感染患儿临床诊治，更准确的检测和疫苗的进一步研发提供参考，以期预防无法通过现有的产时抗生素(intrapartum antibiotic prophylaxis, IAP)治疗策略加以预防的婴儿GBS疾病。</p></sec><sec id="s2"><title>关键词</title><p>B族链球菌，产时抗生素预防策略(IAP)，GBS检测方法，疫苗</p></sec><sec id="s3"><title>Progress in the Outcome Analysis, Detection and Treatment of Group B Streptococcal Disease Infected Newborns<sup> </sup></title><p>Yao Bai, Hongmei Li, Jinmei Ma, Qiao Bai</p><p>Obstetrics and Gynecology, Yan’an University Affiliated Hospital, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/42-1572025x4_hanspub.png" /></p><p>Received: Feb. 16<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 18<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/42-1572025x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Although in recent years, the treatment and prevention of group B streptococcus (GBS) infection has made significant progress, but still GBS infection is an important public health problem, and is an important reason for adverse outcomes in newborns. The GBS vaccines, as an ideal strategy to prevent the GES infection, is in the development stage; some vaccines have entered clinical trials. This article reviews the research progress of incidence, adverse outcomes, serotypes, antibiotic use, drug resistance and detection methods in children with GBS infection, to provide reference for clinical diagnosis and treatment of children with GBS infection, more accurate detection and further development of vaccines, in order to prevent GBS diseases in infants that cannot be prevented by existing intrapartum antibiotic prophylaxis (IAP) treatment strategies.</p><p>Keywords:Group B Streptococcus, Intrapartum Antibiotic Prophylaxis, GBS Detection Method, Vaccine</p><disp-formula id="hanspub.41015-formula19"><graphic xlink:href="//html.hanspub.org/file/42-1572025x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/42-1572025x7_hanspub.png" /> <img src="//html.hanspub.org/file/42-1572025x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>1938年Fry研究发现B族链球菌(Group B streptococcus, GBS)定植导致产后感染心内膜炎，并引起 3 例产妇死亡的不良分娩史，说明GBS导致人类患病 [<xref ref-type="bibr" rid="hanspub.41015-ref1">1</xref>]。1958年，分离在新爱尔兰的3例脑膜炎婴儿脑脊液，发现β溶血性B族链球菌，其中2名患儿死亡，引起人们对GBS的进一步关注 [<xref ref-type="bibr" rid="hanspub.41015-ref2">2</xref>]，由此得知B族链球菌是一种机会致病菌，危及围产期妇女及婴幼儿生命安全。Liu H实验得出中国南方孕妇生殖道GBS阳性率为8%~14% [<xref ref-type="bibr" rid="hanspub.41015-ref3">3</xref>]，Slotved HC等收集13年的B组链球菌样本统计GBS阳性母亲的新生儿带菌率为3. 94%，感染率为2.36% [<xref ref-type="bibr" rid="hanspub.41015-ref4">4</xref>]，而迄今为止最全面的系统性回顾和荟萃分析估计，全球新生儿发病率和死亡率的综合发病率为0.49‰ [<xref ref-type="bibr" rid="hanspub.41015-ref5">5</xref>]。因此进一步探讨B族链球菌感染与新生儿感染的关系，对结局的影响，通过现有的策略加以预防，对降低婴儿感染GBS引起的不良结局和有效预防有重要意义。</p></sec><sec id="s6"><title>2. 感染途径</title><p>1) GBS作为一种机会致病菌，它具有吞噬炎症细胞及释放蛋白质水解酶的作用，直接对感染患者造成损伤，从而孕妇胎膜牵引力下降，患者出现胎膜早破或早产。当胎膜不完整，病原菌进一步通过破裂的胎膜直接进入羊膜腔，胎盘出现感染，直接导致了新生儿感染的发生 [<xref ref-type="bibr" rid="hanspub.41015-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41015-ref7">7</xref>]。</p><p>2) 病原菌的释放也会促进前列腺素和细胞介质释放，促进患者宫缩，从而引患儿出现缺氧窒息及宫内窘迫。并且在分娩的过程中，GBS通过产时的直接传播，也会加加新生儿感染肺炎的风险 [<xref ref-type="bibr" rid="hanspub.41015-ref8">8</xref>]。</p></sec><sec id="s7"><title>3. 新生儿GBS感染情况</title><sec id="s7_1"><title>3.1. 分型</title><p>对于GBS感染导致的新生儿疾病，可根据发病时间分为：新生儿早发性疾病(early-onset GBS disease EOD；0~6天)和新生儿迟发性疾病(late-onset GBS disease，LOD；7岁~90天)。</p><sec id="s7_1_1"><title>3.1.1. 早发型</title><p>GBS感染疾病是发生在新生儿出生后7天内(0~6天)的感染疾病，能从正常无菌部位(例如血液或脑脊液中)检测出B族链球菌 [<xref ref-type="bibr" rid="hanspub.41015-ref9">9</xref>]，多为母亲垂直传播 [<xref ref-type="bibr" rid="hanspub.41015-ref10">10</xref>]。2015年英国早发型GBS感染发生率为0.57/1000 [<xref ref-type="bibr" rid="hanspub.41015-ref11">11</xref>]。早产儿中，早发型感染患儿出生后的6~12小时极易导致败血症、肺炎 [<xref ref-type="bibr" rid="hanspub.41015-ref12">12</xref>]。</p></sec><sec id="s7_1_2"><title>3.1.2. 晚发型</title><p>GBS感染疾病是指发生在新生儿出生7 d~3个月内的感染性疾病，主要是由外界环境及医院获得。LOD的总平均发病率为0.31/1000 [<xref ref-type="bibr" rid="hanspub.41015-ref13">13</xref>]。临床主要表现为脑膜炎且伴随有颅高压、嗜睡、体温升高、运动不协调、智力受损 、皮质盲、脑室炎、瘫痪 、发声困难 、失鸣等，对新生儿生命健康造成严重的影响 [<xref ref-type="bibr" rid="hanspub.41015-ref14">14</xref>]。</p></sec></sec><sec id="s7_2"><title>3.2. 不良结局</title><sec id="s7_2_1"><title>3.2.1. 肺炎</title><p>GBS是新生儿肺炎引起死亡的重要病原体，在早发型肺炎尤甚 [<xref ref-type="bibr" rid="hanspub.41015-ref15">15</xref>]，但应与肺表面张力不足引起的呼吸窘迫综合症鉴别。B族链球菌感染患儿会出现紫绀、呼吸暂停、血压下降、体温不稳等，胸片检查提示云絮状变化与块状阴影，为炎症浸润。若未采取进一步措施，则病情可能恶化，进一步出现代谢改变、神经系统症状等，其中造成新生儿B族链球菌感染致死的主因是呼吸窘迫、代谢紊乱。</p></sec><sec id="s7_2_2"><title>3.2.2. 败血症</title><p>在20世纪90年代，受其GBS感染影响的新生儿中有4%至6%死于新生儿败血症，幸存的婴儿通常有发育障碍，包括精神发育迟滞和听力或视力丧失。临床表现常为发热伴有黄疸、肝脾肿大、呕吐腹胀、皮肤黏膜淤点、肺出血、严重时有呼吸抑制、休克、DIC (弥散性血管内凝血) [<xref ref-type="bibr" rid="hanspub.41015-ref11">11</xref>]。</p></sec><sec id="s7_2_3"><title>3.2.3. 脑膜炎</title><p>GBS是导致该病的主要病原体，其在化脓性脑膜炎的总发病率中占比约25% [<xref ref-type="bibr" rid="hanspub.41015-ref16">16</xref>]，其病程偏长，患儿常伴有神经系统症状，如肢体瘫痪、听力与视力下降、肢体抽搐和脑积水等 [<xref ref-type="bibr" rid="hanspub.41015-ref17">17</xref>]。其发生机制可能为新生儿受到溶血性色素的毒性影响，溶血性色素促进GBS突破肺屏障向周围扩散，突破血脑屏障进入脑组织，促进微血管内皮细胞的急性炎症反应，从而导致严重的GBS性脑膜炎 [<xref ref-type="bibr" rid="hanspub.41015-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.41015-ref19">19</xref>]。</p></sec><sec id="s7_2_4"><title>3.2.4. 新生儿结局的进一步发现</title><p>1) 有研究者指出新生儿早发型GBS疾病与坏死性小肠结肠炎之间有强相关性，母亲为B族链球菌定植者其分娩的新生儿发生坏死性小肠结肠炎的可能性增加了五倍多 [<xref ref-type="bibr" rid="hanspub.41015-ref20">20</xref>]。</p><p>2) 有研究指出GBS患儿治愈后再次入院的原因为多为呼吸系统疾病和传染性疾病，并且更容易出现泌尿生殖和中枢相关的疾病如癫痫和脑瘫 [<xref ref-type="bibr" rid="hanspub.41015-ref21">21</xref>]。</p></sec></sec><sec id="s7_3"><title>3.3. 血清型</title><p>在孕妇中，临床分离株和定殖分离株的血清型有良好的相关性，血清型V (27.5%)为主要血清型，其次是Ia (24.3%)和III (16.5%) GBS有10个不同的血清型，6种GBS血清型导致了99.3%的早发型B族链球菌感染和99.7%的晚发型B族链球菌感染 [<xref ref-type="bibr" rid="hanspub.41015-ref22">22</xref>]。ABCs (主动细菌核酸检测)对美国10个州的选定县的婴儿进行了以人群和实验室为基础的侵入性GBS疾病监测涵盖了439,151例活产婴儿，检测指出 [<xref ref-type="bibr" rid="hanspub.41015-ref23">23</xref>] 90%以上的GBS感染患儿是由血清型Ia，Ib，II，III，IV和V引起的。新生儿早发性疾病以血清型la和III最为常见。新生儿晚发性疾病中，血清型III最为常见。</p></sec><sec id="s7_4"><title>3.4. IAP (产时抗生素预防策略)</title><sec id="s7_4_1"><title>3.4.1. 使用情况</title><p>1973年有指南推荐使用产时抗生素预防策略来减少新生儿B族链球菌疾病的发生，目前产时抗生素预防已被广泛采用，但全球执行产的标准并不一致，有较大的差异。有研究指出在没有应用产时抗生素预防策略的国家，GBS定植产妇所分娩的新生儿中约有1.1%因GBS发生新生儿早发型B族链球菌感染疾病，而在应用产时抗生素预防策略的国家，B族链球菌定植产妇所分娩的新生儿中发生早发型GBS感染的风险降至0.03% [<xref ref-type="bibr" rid="hanspub.41015-ref24">24</xref>]。</p></sec><sec id="s7_4_2"><title>3.4.2. 抗生素预防治疗的最佳使用时长</title><p>抗生素使用首选青霉素G，适用于本次妊娠期间任何时间有GBS菌尿、既往有新生儿患早发型B族链球菌感染、妊娠36~37<sup>+6</sup>周阴道–直肠感染 [<xref ref-type="bibr" rid="hanspub.41015-ref25">25</xref>]。</p><p>2010年美国推荐的围产期B族链球菌指南及2014年新西兰关于围产期B族链球菌(GBS)的指南中均建议晚期B族链球菌筛查阳性的经阴道分娩的产妇在产时应用抗生素预防治疗，且最好在分娩前至少4小时应用，而Lin [<xref ref-type="bibr" rid="hanspub.41015-ref26">26</xref>] 等研究表明使用抗生素预防可有效改善B族链球菌感染的早发性疾病，抗生素应在分娩前至少2小时给药，以期达到最佳预防效果。</p></sec></sec><sec id="s7_5"><title>3.5. 耐药性</title><p>通过分离1727株B族链球菌菌株，分析对抗生素的敏感性，得出四种耐药型分别是红霉素耐药、构成型克林霉素耐药，血清型V耐药，诱导型克林霉素耐药，其中红霉素耐药44.8%，构成型克林霉素耐药20.8% [<xref ref-type="bibr" rid="hanspub.41015-ref22">22</xref>]。谢云 [<xref ref-type="bibr" rid="hanspub.41015-ref27">27</xref>] 同样研究说明结构型耐药(cMLSB)的GBS菌株远大于诱导型耐药(iMLSB)和M型耐药菌株，红霉素耐药占比88.2%，远高于国外。相关研究指出：红霉素耐药，常见的决定基因包括ermB (28 [32.6%])、mef (26 [30.2%])、ermTR (23 [26.7%])和ermT (10 [11.6%])，克林霉素耐药则与ermB (43.1%)、ermTR (35.4%)和ermT (15.4%)相关，最常见的3种多位点序列类型为ST23 (20.0%)、ST19 (5.4%)、ST22 (13.8%) [<xref ref-type="bibr" rid="hanspub.41015-ref28">28</xref>]。</p></sec></sec><sec id="s8"><title>4. GBS检测方法</title><sec id="s8_1"><title>4.1. 微生物学检测法</title><p>包括直接培养法、显色培养法、增菌培养法等。临床广泛应用GBS直接培养，其培养过程繁琐、耗时长，可以进一步分析细菌对抗生素的耐药情况。其准确率不能保证100%，且细菌培养需要18~24小时后观察，因此低菌量较难检出。</p></sec><sec id="s8_2"><title>4.2. 免疫学检测法</title><p>包括：检测GBS抗原的乳胶凝集法、胶体金免疫层析法等，其采用含有多糖荚膜抗体乳胶配备液与相应抗原反应 [<xref ref-type="bibr" rid="hanspub.41015-ref29">29</xref>]，特异性抗体检查抗原的快速检测法，具有快速、低廉的特点，但检出率不高，GBS菌量较少时敏感度降低 。</p></sec><sec id="s8_3"><title>4.3. 分子生物学检测法</title><sec id="s8_3_1"><title>4.3.1. 环介导等温扩增(LAMP)快速检测</title><p>利用少量引物在LAMP试剂盒中进行连续快速基因扩增，在短时间内即可产生大量基因序列拷贝，样本处理后10~15 min内即可完成，其灵敏度和特异度分别为96.7%和100% [<xref ref-type="bibr" rid="hanspub.41015-ref30">30</xref>] 其不能进一步培养细菌监测对抗生素的耐药情况，但适用于GBS DNA含量低、DNA提取困难的临床病例，易于在临床上大规模推广。</p></sec><sec id="s8_3_2"><title>4.3.2. PCR技术</title><p>包括荧光原位杂交技术、PCR列阵技术、实时荧光PCR检测技术、多重PCR等 [<xref ref-type="bibr" rid="hanspub.41015-ref31">31</xref>]，提高了GBS检测的检测效率及准确性，有效避免交叉现象，样本处理后根据基因型设计出30余引物和探针，可同时检测GBS血清及基因，10~15 min检测可出现结果 [<xref ref-type="bibr" rid="hanspub.41015-ref32">32</xref>]，能在临床筛查高危孕妇及对新生儿感染的诊治中发挥重要作用，其检测费用相对昂贵，对技术人员操作要求较高。</p><p>蔡晓沂等人 [<xref ref-type="bibr" rid="hanspub.41015-ref33">33</xref>] 使用核酸扩增技术来检测GBS患者带菌情况，采用即时荧光探针，操作上可以反复检测，通过定量方法捕获被探针识别的基因 [<xref ref-type="bibr" rid="hanspub.41015-ref34">34</xref>]。2~4 h即可完成检测，大大快于传统筛查，可以用来做临产前快速检测。</p></sec></sec></sec><sec id="s9"><title>5. 疫苗研究进展</title><p>尽管GBS感染的诊断和治疗取得了重大进展，个人卫生标准也有所改善，但这种病原体仍然是一个全球性的健康问题。因此，一种有效的GBS疫苗将加强现有的策略，有望预防无法通过现有的策略加以预防婴儿GBS疾病，尤其是新生儿晚发型B族链球菌感染疾病。2014年，世界卫生组织召开了第一次GBS疫苗开发协商会议。虽然IAP (产时抗生素预防策略)是有效的，候选疫苗的应用需要非常大的三期临床疗效试验，基于免疫应答与临床保护之间良好的相关性，一些专家建议基于免疫原性试验可以批准GBS疫苗。在此之前根据免疫原性测定结果，在英国成功引进了脑膜炎奈瑟菌C组结合疫苗 [<xref ref-type="bibr" rid="hanspub.41015-ref35">35</xref>]。因此，开发GBS疫苗迫切需要临床免疫原性测定的标准化，对比于肺炎球菌多糖结合疫苗(PCV)疫苗，现有两种标准的免疫学方法，</p><sec id="s9_1"><title>5.1. 测定特异性抗体的酶联免疫吸附试验(ELISA)</title><p>其缺点是由于ELISA的应用不能区分低亲和低功能抗体和高亲和抗体，ELISAs可能不足以确定抗体的功能质量，此外，必须优化CPS在ELISA板上的固定，因此用于测定血清型特异性GBS抗体的特异性ELISA方案设计还需进一步优化。</p></sec><sec id="s9_2"><title>5.2. 调理吞噬细胞杀伤试验(OPKA)</title><p>经典的OPKA是对大量样本中几个血清型特异性的OPKA进行检查的繁琐程序，该检测方法已进一步简化，从单一OPKA简化为多路OPKA，以减少检测时间和检测所需的血清量 [<xref ref-type="bibr" rid="hanspub.41015-ref36">36</xref>]。利用多路复用OPKA的技术优势，三倍多路复用OPKA (GBS-mopa)已被开发、标准化并验证在新生儿中应用 [<xref ref-type="bibr" rid="hanspub.41015-ref37">37</xref>]。这一标准化的GBS-mopa方案使得对血清型Ia、III和v的GBS疫苗免疫原性进行实际、大规模的评估成为可能。因此我们需要进一步有关GBS血清型和基因型分布的全球流行病学研究，用以开发一套额外的GBS-mopa，包括所有可能的疫苗血清型，并且在GBS疫苗的许可和实施之前和之后，仍需不断评估和监测疫苗的有效性和疾病发生率的变化。</p></sec></sec><sec id="s10"><title>6. 小结</title><p>1) 患儿一旦发生侵袭性GBS感染，往往预后不佳，致残率和病死率较高。早发型感染患儿出生后的6~12小时极易导致败血症、肺炎，晚发型进一步引起神经系统病变，不同疾病时患儿早期临床表现有所不同，但是以上临床表现并无特异性，需要注意。血清型分离发现新生儿早发性疾病以血清型la和III最为常见。新生儿晚发性疾病中，血清型III最为常见。2) 目前IAP仍是控制GBS感染的主要手段，但耐药性日渐严重，且对新生儿晚发型B族链球菌感染疾病的预防效果不明显。3) 同时GBS检测的准确性和高效性需进一步加强，微生物学检测法培养过程繁琐、耗时长，其优点可以进一步分析细菌对抗生素的耐药情况；PCR法是较快速准确的筛查方法，望用于产房快速检查。4) GBS疫苗是预防GBS感染的理想策略，随着研究疫苗有望早日投入市场。但还需克服伦理、临床免疫原性测定的标准化、血清型覆盖率等诸多问题。</p></sec><sec id="s11"><title>文章引用</title><p>白 瑶,李红梅,马金梅,白 乔. B族链球菌病感染新生儿结局分析及检测治疗进展Progress in the Outcome Analysis, Detection and Treatment of Group B Streptococcal Disease Infected Newborns[J]. 临床医学进展, 2021, 11(03): 1112-1118. https://doi.org/10.12677/ACM.2021.113159</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41015-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">朱敏, 范建霞, 程利南. 围产期B族链球菌感染的研究进展[J]. 中华妇产科杂志, 2005(2): 68-72.</mixed-citation></ref><ref id="hanspub.41015-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">马延敏, 吴连方. B族链球菌对母婴健康的影响及诊断和防治[J]. 中华围产医学杂志, 1998(2): 109-111.</mixed-citation></ref><ref id="hanspub.41015-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Liu, H., Zeng, H., Wang, W., et al. (2015) Estimating the Burden of Invasive Group B Streptococcal Disease in Young Infants in Southern Mainland China: An Observational Study. International Journal of Clinical &amp; Experimental Medicine, 8, 13699-13707.</mixed-citation></ref><ref id="hanspub.41015-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Christian, S.H. and Steen, H. (2020) The Epidemiology of Invasive Group B Streptococcus in Denmark from 2005 to 2018. Frontiers in Public Health, 8, 40. &lt;br&gt;https://doi.org/10.3389/fpubh.2020.00040</mixed-citation></ref><ref id="hanspub.41015-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Russell, N.J., Seale, A.C., O’Sullivan, C., et al. (2017) Risk of Early-Onset Neonatal Group B Streptococcal Disease with Maternal Colonization Worldwide: Systematic Review and Meta-Analyses. Clinical Infectious Diseases, 65, S152-S159. &lt;br&gt;https://doi.org/10.1093/cid/cix655</mixed-citation></ref><ref id="hanspub.41015-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">陈小丽, 吴佳音, 陈玲, 等. 3种B族链球菌筛查方法在孕晚期筛查中的应用[J]. 临床检验杂志, 2019, 37(4): 290-292.</mixed-citation></ref><ref id="hanspub.41015-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李春燕, 王芳, 杜鹃, 等. 新生儿B族链球菌感染危险因素研究[J]. 上海医学, 2018, 41(3): 161-164.</mixed-citation></ref><ref id="hanspub.41015-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">邱海凡, 王剑平, 王荣跃. 妊娠晚期妇女B族链球菌感染危险因素分析[J]. 中国消毒学杂志, 2018, 35(4): 283-285.</mixed-citation></ref><ref id="hanspub.41015-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Anthony, B.F., Okada, D.M. and Hobel, C.J. (1979) Epidemiology of the Group B Streptococcus: Maternal and Nosocomial Sources for Infant Acquisitions. The Journal of Pediatrics, 95, 431-436.  
&lt;br&gt;https://doi.org/10.1016/S0022-3476(79)80530-2</mixed-citation></ref><ref id="hanspub.41015-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hung, L.C., Kung, P.T., Chiu, T.H., et al. (2018) Risk Factors for Neonatal Early-Onset Group B Streptococcus-Related Diseases after the Implementation of a Universal Screening Program in Taiwan. BMC Public Health, 18, 438. &lt;br&gt;https://doi.org/10.1186/s12889-018-5358-0</mixed-citation></ref><ref id="hanspub.41015-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">American College of Obstetricians and Gynecologists (2020) Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797. Obstetrics &amp; Gynecology, 135, e51-e72.  
&lt;br&gt;https://doi.org/10.1097/AOG.0000000000003668</mixed-citation></ref><ref id="hanspub.41015-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">冯艳. 未足月胎膜早破合并下生殖道感染对母婴结局的影响[J]. 中国妇幼保健, 2015, 30(9): 1379-1380.</mixed-citation></ref><ref id="hanspub.41015-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">王超, 赵扬玉. 规范临床用药, 改善母婴结局: 美国《预防新生儿早发型B族链球菌病: ACOG委员会共识》解读[J]. 协和医学杂志, 2020, 11(4): 402-407.</mixed-citation></ref><ref id="hanspub.41015-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Centers for Disease Control and Prevention (CDC) (2007) Perinatal Group B Streptococcal Disease after Universal Screening Recommendations—United States, 2003-2005. MMWR Morbidity &amp; Mortality Weekly Report, 56, 701-705.</mixed-citation></ref><ref id="hanspub.41015-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">杨磊, 时春艳. 围产期B族溶血性链球菌的筛查与处理[J]. 中华产科急救电子杂志, 2017, 6(3): 147-153.</mixed-citation></ref><ref id="hanspub.41015-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">鞠慧群, 贝斐, 孙建华. B族链球菌感染所致新生儿化脓性脑膜炎临床特点分析[J]. 中华新生儿科杂志, 2016, 31(3): 178-181.</mixed-citation></ref><ref id="hanspub.41015-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">谭举方, 朱晓芳, 周艳玲, 等. 新生儿B组链球菌脑膜炎60例临床诊治探讨[J]. 中国妇幼保健, 2014, 29(1): 65-67.</mixed-citation></ref><ref id="hanspub.41015-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Lembo, A., Gurney, M.A., Burnside, K., et al. (2010) Regulation of CovR Expression in Group B Streptococcus Impacts Blood-Brain Barrier Penetration. Molecular Microbiology, 77, 431-443.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2958.2010.07215.x</mixed-citation></ref><ref id="hanspub.41015-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Doran, K.S., Liu, G.Y. and Nizet, V. (2003) Group B Streptococcal Beta-Hemolysin/Cytolysin Activates Neutrophil Signaling Pathways in Brain Endothelium and Contributes to Development of Meningitis. The Journal of Clinical Investigation, 112, 736-744. &lt;br&gt;https://doi.org/10.1172/JCI200317335</mixed-citation></ref><ref id="hanspub.41015-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">时春艳, 曲首辉, 杨磊, 等. 妊娠晚期孕妇B族链球菌带菌状况的检测及带菌对妊娠结局的影响[J]. 中华妇产科杂志, 2010, 45(1): 12-16.</mixed-citation></ref><ref id="hanspub.41015-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Khodaei, F., Najafi, M., Hasani, A., et al. (2018) Pilus-Encoding Islets in S. agalactiae and Its Association with Antibacterial Resistance and Serotype Distribution. Microbial Pathogenesis, 116, 189-194.  
&lt;br&gt;https://doi.org/10.1016/j.micpath.2018.01.035</mixed-citation></ref><ref id="hanspub.41015-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Mei, L.S., Yong, Z., Bum, A.K., et al. (2018) Status of Group B Streptococcal Vaccine Development. Clinical and Experimental Vaccine Research, 7, 76-81. &lt;br&gt;https://doi.org/10.7774/cevr.2018.7.1.76</mixed-citation></ref><ref id="hanspub.41015-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Nanduri, S.A., Petit, S., Smelser, C., et al. (2019) Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance. JAMA Pediatrics, 173, 224-233. &lt;br&gt;https://doi.org/10.1001/jamapediatrics.2018.4826</mixed-citation></ref><ref id="hanspub.41015-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Madrid, L., Seale, A.C., Kohli-Lynch, M., et al. (2017) Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-Analyses. Clinical Infectious Diseases, 65, S160-S172.  
&lt;br&gt;https://doi.org/10.1093/cid/cix656</mixed-citation></ref><ref id="hanspub.41015-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">ACOG (2019) Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion Summary, Number 782. Obstetrics &amp; Gynecology, 134, 206-210.</mixed-citation></ref><ref id="hanspub.41015-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lin, F.Y.C., Brenner, R.A., Johnson, Y.R., et al. (2001) The Effectiveness of Risk-Based Intrapartum Chemoprophylaxis for the Prevention of Early-Onset Neonatal Group B Streptococcal Disease. American Journal of Obstetrics &amp; Gynecology, 184, 1204-1210. &lt;br&gt;https://doi.org/10.1067/mob.2001.113875</mixed-citation></ref><ref id="hanspub.41015-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">谢云, 杨柳, 屈蕾, 等. 围生期孕妇生殖道B族链球菌耐药性变迁及血清型分布研究[J]. 国际妇产科学杂志, 2019, 46(6): 657-660.</mixed-citation></ref><ref id="hanspub.41015-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Metcalf, B.J., et al. (2017) Short-Read Whole Genome Sequencing for Determination of Antimicrobial Resistance Mechanisms and Capsular Serotypes of Current Invasive Streptococcus agalactiae Recovered in the USA. Clinical Microbiology and Infection, 23, 574.e7-574.e14.</mixed-citation></ref><ref id="hanspub.41015-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Konikkara, K.P., Baliga, S., Shenoy, S., et al. (2014) Evaluation of Culture, Antigen Detection and Polymerase Chain Reaction for Detection of Vaginal Colonization of Group B Streptococcus (GBS) in Pregnant Women. Journal of Clinical &amp; Diagnostic Research, 8, 47.</mixed-citation></ref><ref id="hanspub.41015-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Skowronski, D.M., Chambers, C., Sabaiduc, S., et al. (2017) Interim Estimates of 2016/17 Vaccine Effectiveness against Influenza A(H3N2), Canada, January 2017. Eurosurvllance, 22, 30460.  
&lt;br&gt;https://doi.org/10.2807/1560-7917.ES.2017.22.6.30460</mixed-citation></ref><ref id="hanspub.41015-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Poyart, C., Tazi, A., Reglier-Poupet, H., et al. (2007) Multiplex PCR Assay for Rapid and Accurate Capsular Typing of Group B Streptococci. Journal of Clinical Microbiology, 45, 1985-1988. &lt;br&gt;https://doi.org/10.1128/JCM.00159-07</mixed-citation></ref><ref id="hanspub.41015-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Clarke, C., O’Connor, L., Carre-Skinner, H., et al. (2016) Development and Performance Evaluation of a Recombinase Polymerase Amplification Assay for the Rapid Detection of Group B Streptococcus. BMC Microbiology, 16, Article No. 221. &lt;br&gt;https://doi.org/10.1186/s12866-016-0836-y</mixed-citation></ref><ref id="hanspub.41015-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">蔡晓沂, 钟镐镐, 王秀艳, 等. 快速、准确的B族链球菌检测——即时荧光探针核酸扩增技术的应用[J]. 现代预防医学, 2013(13): 163-165+176.</mixed-citation></ref><ref id="hanspub.41015-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Parham, N.J., Picard, F.J., Peytavi, R., et al. (2007) Specific Magnetic Bead-Based Capture of Genomic DNA from Clinical Samples: Application to the Detection of Group B Streptococci in Vaginal/Anal Swabs. Clinical Chemistry, 53, 1570-1576. &lt;br&gt;https://doi.org/10.1373/clinchem.2007.091389</mixed-citation></ref><ref id="hanspub.41015-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Balmer, P., Borrow, R. and Miller, E. (2002) Impact of Meningococcal C Conjugate Vaccine in the UK. Journal of Medical Microbiology, 51, 717-722. &lt;br&gt;https://doi.org/10.1099/0022-1317-51-9-717</mixed-citation></ref><ref id="hanspub.41015-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Choi, M.J., et al. (2018) Development of a Multiplexed Opsonophagocytic Killing Assay (MOPA) for Group B Streptococcus. Human Vaccines &amp; Immunotherapeutics, 14, 67-73.</mixed-citation></ref><ref id="hanspub.41015-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Choi, M.J., Noh, J.Y., Cheong, H.J., Kim, W.J., Lin, S.M., Zhi, Y., et al. (2018) Development of a Multiplexed Opsonophagocytic Killing Assay (MOPA) for Group B Streptococcus. Human Vaccines &amp; Immunotherapeutics, 14, 67-73.  
&lt;br&gt;https://doi.org/10.1080/21645515.2017.1377379</mixed-citation></ref></ref-list></back></article>